Minerva Neurosciences, Inc. — Q3 2016 Form 10-Q
Business context and period. This clinical-stage biopharmaceutical company reported for the quarter and nine months ended September 30, 2016. Its four CNS candidates are MIN-101 (schizophrenia), MIN-202 (insomnia and major depressive disorder, co-developed with Janssen), MIN-117 (major depressive disorder) and MIN-301 (Parkinson’s disease). No candidate is approved for sale, and the company had no product or licensing revenue.
Financial performance and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $5.85M | $3.83M | $13.94M | $12.27M |
| General and administrative expense | $2.38M | $1.88M | $7.01M | $5.64M |
| Net loss | $8.42M | $5.94M | $21.64M | $18.64M |
| Basic and diluted loss per share | $0.24 | $0.24 | $0.71 | $0.81 |
| Operating cash used | Not provided by quarter | Not provided by quarter | $16.76M | $17.67M |
- Margins: Not meaningful because the company had no revenue.
- Cash and liquidity: Cash and cash equivalents were $91.85M at September 30, 2016, versus $14.28M at December 31, 2015. Marketable securities declined from $17.92M to zero as securities matured or were redeemed. Management expected available cash to fund operations into 2018, but said further capital would be needed for later-stage development.
- Cash flows, nine months: Investing activities provided $17.82M, primarily from marketable-security maturities; financing activities provided $76.51M, mainly from equity issuance and warrant exercises. Cash increased $77.57M to $91.85M.
- Debt: The balance sheet reported $9.80M of notes payable, split between $4.75M current and $5.05M noncurrent. Term A loan principal was $9.61M, at a fixed 7.05% rate, with maturity on August 1, 2018. The loans are secured by substantially all assets other than intellectual property. The company declined the remaining $5M borrowing availability.
- Equity and deficit: Stockholders’ equity was $113.14M and accumulated deficit was $123.45M. Shares outstanding increased to 34.81M from 24.72M at year-end 2015.
Material changes versus the prior comparable period
- Q3 net loss increased by $2.48M year over year; nine-month net loss increased by $3.00M. Q3 R&D rose $2.02M, mainly due to MIN-202 Phase II preparation, partly offset by lower costs after MIN-101 and MIN-117 trials concluded. Nine-month R&D rose $1.67M, reflecting MIN-202, MIN-117 and MIN-301 spending, partly offset by completion of the MIN-101 Phase IIb trial.
- G&A increased $0.50M in Q3 and $1.37M for the nine months, primarily due to professional fees and personnel costs. Stock-based compensation rose to $2.56M for the nine months from $1.51M.
- Equity financing strengthened cash: the June public offering generated $53.67M net; warrant exercises generated $22.22M gross; and a director private placement generated approximately $1.00M gross. These transactions contributed to the higher share count and diluted existing holders.
- Operating cash use improved by approximately $0.91M year over year for the nine months, despite a larger net loss, in part reflecting accrued collaborative expenses and non-cash charges.
Outlook, management commentary and risks
- Management expected MIN-101 Phase III testing in schizophrenia to begin in mid-2017, subject to discussions with U.S. and European regulators. The Phase IIb trial met its primary endpoint for negative symptoms; extension results were supportive, but the filing cautions that early- and mid-stage results may not predict later-stage outcomes. QTcF-related discontinuation criteria led to discontinuation of two higher-dose patients in the core trial; no additional patients were discontinued in the extension.
- FDA accepted the MIN-117 IND in September 2016, with U.S. trials expected to begin in 2017. The European Phase IIa study was designed for signal detection and was not powered to show statistically significant differences versus placebo.
- MIN-202 Phase II trials in insomnia and MDD were anticipated to begin in early 2017. After reaching “Decision Point 2” with Janssen, Minerva expected up to $15.5M in additional expense and payments of up to $19.0M to Janssen as eligible development costs are incurred. Its share of development costs is subject to contractual caps and milestones.
- MIN-301 remained in preclinical development; further toxicology and manufacturing work would precede regulatory filings and Phase I trials.
- The company expects continued operating losses and negative operating cash flows, with R&D likely to increase. It may need additional financing or partnerships; financing may dilute shareholders, impose restrictive terms, or be unavailable, potentially requiring programs to be delayed, scaled back or discontinued.
- Other significant risks include clinical failure or adverse safety findings, regulatory delays or rejection, reliance on CROs and contract manufacturers, dependence on MTPC and Janssen licenses, intellectual-property risks, competition, and foreign-currency exposure. The filing reported no known litigation expected to have a material adverse effect and no off-balance-sheet arrangements. Management assessed disclosure controls as effective.
Important facts for investors to verify
- Whether the stated cash runway into 2018 remains adequate after MIN-202 commitments, planned clinical trials, and scheduled loan principal payments.
- Progress, regulatory feedback, timing and funding needs for MIN-101 Phase III and planned MIN-117 and MIN-202 trials.
- Actual eligible MIN-202 development costs and payments under the Janssen agreement, including milestone terms and cost caps.
- Future financing needs and the effect of additional share issuance, warrants, options and other dilution.
- Clinical safety and efficacy evidence, particularly QTcF monitoring for MIN-101 and whether findings from earlier-stage studies are confirmed in larger trials.